Get notified of page updates
Education > XRAY > Search Results

FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you. XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program

How To Use XRAY
Search by Topic Submit an Article for Review

All XRAYs

61 through 70 of 311

Relevance: High

Research Timeline: Post Approval

View Related Clinical Trials

Update : PARP inhibitors withdrawn as third-line or later treatment for recurrent ovarian cancer

Relevance: High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: people with recurrent ovarian cancer who have received 3 or more prior lines of treatment and who have an inherited or tumor mutation in BRCA1 or BRCA2 or whose tumor is HRD positive

Survival data from a clinical trial signaled that PARP inhibitors may not work as well as chemotherapy for patients with recurrent ovarian cancer who have received three or more lines of treatment. As a result, FDA approvals have been withdrawn for PARP inhibitors in this setting.  This does not affect PARP inhibitor approvals for use as maintenance therapy for ovarian cancer. (Posted 10/4/22)

Este artículo está disponible en español.

Read More

Relevance: High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Study : Acupuncture may ease breast cancer treatment side effects

Relevance: High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: People considering acupuncture for managing breast cancer treatment symptoms.

Acupuncture can ease some symptoms of breast cancer treatment. Multiple studies found that acupuncture is a safe and effective strategy to manage certain symptoms but also called for more rigorous research on the topic. (Posted 9/28/22) Este artículo está disponible en español.

Read More

Relevance: Medium

Research Timeline: Post Approval

View Related Clinical Trials

Update : FDA reports on new cancers linked to breast implants

Relevance: Medium

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: People with breast implants

New cancers have been found in women with both textured and smooth implants that are filled with either saline or silicone. These cancers are extremely rare. The FDA has reported cases of a type of skin cancer and blood cancers in the scar tissue that forms around breast implants. The newly reported lymphomas are different from the previously reported breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). (Posted 9/27/22). Este artículo está disponible en español.

Read More

Relevance: Medium-High

Strength of Science: Medium-High

Study : Expanding Medicaid reduced racial disparities among people with metastatic breast cancer

Relevance: Medium-High

Strength of Science: Medium-High

Most relevant for: People diagnosed with de novo stage 4 breast cancer and people who live in states that have not expanded Medicaid.

The Affordable Care Act allowed more people to access insurance through Medicaid. This study found the expansion of care improved survival and decreased mortality among people of color with de novo stage 4 (stage 4 at the time of initial diagnosis) breast cancer.  (Posted 9/13/2022). Este artículo está disponible en español.

Read More

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Human Research

View Related Clinical Trials

Study : PARP inhibitor treatment for metastatic prostate cancer shows most benefit in men with inherited BRCA mutations

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Human Research

View Related Clinical Trials

Most relevant for: People with metastatic castration resistant prostate cancer who have an inherited or tumor mutation in BRCA2.

This study looked at the benefit of using the PARP inhibitor niraparib to treat metastatic castration-resistant prostate cancer (mCRPC). Participants included those with an inherited or tumor mutation in BRCA1 or BRCA2 or an inherited or tumor mutation in another gene that affects DNA repair. Participants with an inherited or tumor mutation in BRCA1 or BRCA2 had better survival compared to those without a BRCA mutation. Side effects from niraparib were common, and consistent with previous reports for PARP inhibitors.  (posted 9/6/2022)

Este artículo está disponible en español.

Read More

Relevance: High

Strength of Science: High

Research Timeline: Post Approval

View Related Clinical Trials

Study : Screening for pancreatic cancer detects early-stage disease and improves survival

Relevance: High

Strength of Science: High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: People at increased risk for pancreatic cancer because of family history or an inherited mutation.

A research study has shown that screening for pancreatic cancer in people with an inherited mutation or family history was able to detect early-stage pancreatic cancers and improve survival. These results will likely change pancreatic cancer screening guidelines for high-risk individuals (Posted 8/30/22)

Este artículo está disponible en español.

Read More

Relevance: High

Strength of Science: Medium-High

View Related Clinical Trials

Study : Clinical trial eligibility excludes more Black than white patients

Relevance: High

Strength of Science: Medium-High

View Related Clinical Trials

Most relevant for: People with pancreatic cancer who are interested in participating in a clinical trial

Eligibility criteria stating who can and cannot participate in clinical trials are necessary. However, traditional eligibility criteria have led to the exclusion of Black people in pancreatic cancer clinical trials. This exclusion restricts patient access to new drugs and limits the ability to generalize results to the population of patients who will ultimately use the drug. Revising eligibility criteria, especially for patients with pancreatic cancer, may improve clinical trial access among Black people. (Posted 8/23/22)

Este artículo está disponible en español.

Read More

Relevance: High

Quality of Writing: High

View Related Clinical Trials

Article : Rise in endometrial cancer affects Black women more than white women

Relevance: High

Quality of Writing: High

View Related Clinical Trials

Most relevant for: People concerned about their risk for endometrial cancer

The New York Times calls attention to the increase in a type of cancer of the uterus called endometrial cancer and how it disproportionately affects Black women. The article provides useful information about endometrial cancer while raising awareness of a significant and growing health disparity.  (Posted 8/16/22)

Este artículo está disponible en español.

Read More

Relevance: Medium-High

Strength of Science: High

Research Timeline: Post Approval

View Related Clinical Trials

Study : Physical activity may decrease fatigue associated with cancer treatment

Relevance: Medium-High

Strength of Science: High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: Cancer patients who are experiencing fatigue related to cancer or its treatment.

Many cancer survivors experience fatigue during and after they complete treatment. This study looked at the effect of home-based physical activity on fatigue in cancer survivors. It also looked at whether frequent counseling encouraged people to start and continue their exercise routines.  (Posted 8/1/22). Este artículo está disponible en español.

Read More

Relevance: High

Quality of Writing: Medium-High

Article : How your ovarian cancer diagnosis can help your relatives

Relevance: High

Quality of Writing: Medium-High

Most relevant for: People diagnosed with ovarian cancer

This media article provides tips from experts and the CDC for talking to family members after a diagnosis of ovarian cancer. It highlights which family members may be at risk of developing ovarian cancer or passing on genes that increase risk. The article provides links to resources, talking points, alternative methods of communication and potential reactions. (Posted 7/28/22)

Este artículo está disponible en español.

Read More